Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/119027

Author :

Publish date : 2025-12-15 21:28:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

Second Oral Antibiotic for Gonorrhea Gets FDA Green Light

Lung Cancer Screening Follow-Up Often Inadequate

Related Posts

Six Midlife Depressive Symptoms Tied to Dementia

Not Everyone Gets a Mortality Benefit From Reducing Saturated Fats, Study Says

FDA Approves Sexual Desire Drug for Postmenopausal Women

Aspiring Neurosurgeon Died in Brown Campus Shooting

Smartphone-Delivered Digital Therapy Improved Anxiety Symptoms

Lung Cancer Screening Follow-Up Often Inadequate

Six Midlife Depressive Symptoms Tied to Dementia

Not Everyone Gets a Mortality Benefit From Reducing Saturated Fats, Study Says

FDA Approves Sexual Desire Drug for Postmenopausal Women

Aspiring Neurosurgeon Died in Brown Campus Shooting

Smartphone-Delivered Digital Therapy Improved Anxiety Symptoms

Lung Cancer Screening Follow-Up Often Inadequate

Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

Second Oral Antibiotic for Gonorrhea Gets FDA Green Light

Categories

Archives